Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version o | AMLN Message Board Posts


AMLN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  74167 of 74175  at  6/23/2016 9:58:43 AM  by

seemiketalk


Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of ByettaŽ (Exenatide Injection) in the United States (wow, that did not take long - but at least they finally made the Bydureon Pen....lol)

Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta® (Exenatide Injection) in the United States

JERUSALEM--()--Teva Pharmaceuticals USA, Inc., (NYSE and TASE:TEVA) today announced that they have settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to AstraZeneca’s US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca’s BYETTA® (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA® described in Teva’s ANDA No. 205984 in the United States.

The settlement allows Teva to commercialize its generic version of BYETTA® (exenatide injection) in the U.S. beginning October 15, 2017 or earlier under certain circumstances. All other terms of the agreement are confidential.

BYETTA® (exenatide injection) is an injectable product used to treat type 2 diabetes.

Teva remains committed to strengthening its presence in its generic injectable business globally. Teva continues investment in new, and higher-value generic injectable products. With approximately 370 generic medicines available, Teva has the largest portfolio of FDA-approved generic products and continues to bring new products to market for the patients who need them.



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 654 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...